Literature DB >> 16412017

Differential immune effects mediated by Toll-like receptors stimulation in precursor B-cell acute lymphoblastic leukaemia.

Sophie L Corthals1, Kristin Wynne, Kevin She, Hiromi Shimizu, Darko Curman, Kristy Garbutt, Gregor S D Reid.   

Abstract

Acute lymphoblastic leukaemia (ALL) is the most common paediatric malignancy and, although current therapy is widely effective, relapse remains a significant clinical problem for which new treatment strategies are required. The ligation of Toll-like receptors (TLR) on antigen-presenting cells stimulates the generation of strong T-cell helper type 1 (Th1) adaptive immune responses. Although TLR9 ligation has been shown to enhance immunogenicity of a number of leukaemia cell types, there have been few reports of the effects mediated through other TLR. In this study we analysed both the expression of TLR by B-cell precursor ALL cell lines and the effects of individual TLR ligation on the ability of ALL cells to stimulate allogeneic T cells. While ligation of TLR2, TLR 7 and TLR9 led to detectable changes in ALL costimulatory molecule expression, only TLR2 and TLR9 stimulation influenced T-cell responses. The TLR2 ligand Pam3CysSerLys4 provoked the most significant changes in T-cell response, dramatically augmenting interferon-gamma production. These results suggest that TLR ligands, in addition to TLR9 agonists, may provide a strategy to enhance the generation of anti-ALL immune activity by skewing responding T cells towards a Th1 response.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16412017     DOI: 10.1111/j.1365-2141.2005.05893.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  10 in total

Review 1.  Toll-like receptors: lessons to learn from normal and malignant human B cells.

Authors:  David Chiron; Isabelle Bekeredjian-Ding; Catherine Pellat-Deceunynck; Régis Bataille; Gaëtan Jego
Journal:  Blood       Date:  2008-06-30       Impact factor: 22.113

2.  In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors.

Authors:  Céline Berthon; Virginie Driss; Jizhong Liu; Klaudia Kuranda; Xavier Leleu; Nathalie Jouy; Dominique Hetuin; Bruno Quesnel
Journal:  Cancer Immunol Immunother       Date:  2010-09-04       Impact factor: 6.968

3.  Highlights of the First International "Immunotherapy in Pediatric Oncology: Progress and Challenges" Meeting.

Authors:  Christian M Capitini; Laurence J N Cooper; R Maarten Egeler; Rupert Handgretinger; Franco Locatelli; Paul M Sondel; Crystal L Mackall
Journal:  J Pediatr Hematol Oncol       Date:  2009-04       Impact factor: 1.289

Review 4.  Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease.

Authors:  Valerie I Brown; Alix E Seif; Gregor S D Reid; David T Teachey; Stephan A Grupp
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

5.  Aberrant expression of functional BAFF-system receptors by malignant B-cell precursors impacts leukemia cell survival.

Authors:  Sara Maia; Marc Pelletier; Jixin Ding; Yen-Ming Hsu; Stephen E Sallan; Sambasiva P Rao; Lee M Nadler; Angelo A Cardoso
Journal:  PLoS One       Date:  2011-06-08       Impact factor: 3.240

Review 6.  Toll-like receptors in the pathogenesis of human B cell malignancies.

Authors:  Johana M Isaza-Correa; Zheng Liang; Anke van den Berg; Arjan Diepstra; Lydia Visser
Journal:  J Hematol Oncol       Date:  2014-08-12       Impact factor: 17.388

Review 7.  Heterogeneity of Toll-like receptor 9 signaling in B cell malignancies and its potential therapeutic application.

Authors:  Ling Bai; Wei Chen; Jingtao Chen; Wei Li; Lei Zhou; Chao Niu; Wei Han; Jiuwei Cui
Journal:  J Transl Med       Date:  2017-02-27       Impact factor: 5.531

8.  Differential Depletion of Bone Marrow Resident B-ALL after Systemic Administration of Endosomal TLR Agonists.

Authors:  Sumin Jo; Abbas Fotovati; Jesus Duque-Afonso; Michael L Cleary; Peter van den Elzen; Alix E Seif; Gregor S D Reid
Journal:  Cancers (Basel)       Date:  2020-01-10       Impact factor: 6.639

9.  Continuous Complete Remission in Two Patients with Acute Lymphoblastic Leukemia and Severe Fungal Infection Following Short-Term, Dose-Reduced Chemotherapy.

Authors:  Florian Lüke; Dennis C Harrer; Joachim Hahn; Matthias Grube; Tobias Pukrop; Wolfgang Herr; Albrecht Reichle; Daniel Heudobler
Journal:  Front Pharmacol       Date:  2021-06-02       Impact factor: 5.810

10.  ETV6/RUNX1 Fusion Gene Abrogation Decreases the Oncogenicity of Tumour Cells in a Preclinical Model of Acute Lymphoblastic Leukaemia.

Authors:  Adrián Montaño; Jose Luis Ordoñez; Verónica Alonso-Pérez; Jesús Hernández-Sánchez; Sandra Santos; Teresa González; Rocío Benito; Ignacio García-Tuñón; Jesús María Hernández-Rivas
Journal:  Cells       Date:  2020-01-15       Impact factor: 6.600

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.